Zhongzhu Medical Holdings Co Ltd
Zhongzhu Healthcare Holding Co.,Ltd engages in the research and development, production, and sale of drugs in China. The company offers ophthalmology drugs, including Pearl eye drops, Sodium Cromolyn eye drops, Acyclovir eye drops, Hydroxybenzone Hydrochloride eye drops, Acyclovir dispersible tablets, and Gatifloxacin tablets; and products related to tumor treatment. It is also involved in produc… Read more
Zhongzhu Medical Holdings Co Ltd (600568) - Net Assets
Latest net assets as of September 2025: CN¥1.71 Billion CNY
Based on the latest financial reports, Zhongzhu Medical Holdings Co Ltd (600568) has net assets worth CN¥1.71 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.07 Billion) and total liabilities (CN¥355.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.71 Billion |
| % of Total Assets | 82.82% |
| Annual Growth Rate | 13.93% |
| 5-Year Change | -56.21% |
| 10-Year Change | -34.11% |
| Growth Volatility | 87.23 |
Zhongzhu Medical Holdings Co Ltd - Net Assets Trend (1998–2024)
This chart illustrates how Zhongzhu Medical Holdings Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhongzhu Medical Holdings Co Ltd (1998–2024)
The table below shows the annual net assets of Zhongzhu Medical Holdings Co Ltd from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.74 Billion | -32.72% |
| 2023-12-31 | CN¥2.59 Billion | -11.79% |
| 2022-12-31 | CN¥2.94 Billion | -21.24% |
| 2021-12-31 | CN¥3.73 Billion | -6.31% |
| 2020-12-31 | CN¥3.98 Billion | +2.26% |
| 2019-12-31 | CN¥3.89 Billion | -8.57% |
| 2018-12-31 | CN¥4.26 Billion | -30.74% |
| 2017-12-31 | CN¥6.15 Billion | +2.23% |
| 2016-12-31 | CN¥6.01 Billion | +127.31% |
| 2015-12-31 | CN¥2.65 Billion | +2.54% |
| 2014-12-31 | CN¥2.58 Billion | +118.82% |
| 2013-12-31 | CN¥1.18 Billion | +14.70% |
| 2012-12-31 | CN¥1.03 Billion | +12.22% |
| 2011-12-31 | CN¥915.88 Million | +23.31% |
| 2010-12-31 | CN¥742.77 Million | +9.67% |
| 2009-12-31 | CN¥677.27 Million | +9.90% |
| 2008-12-31 | CN¥616.24 Million | +19.66% |
| 2007-12-31 | CN¥514.98 Million | +7.46% |
| 2006-12-31 | CN¥479.24 Million | -14.23% |
| 2005-12-31 | CN¥558.76 Million | +14.15% |
| 2004-12-31 | CN¥489.48 Million | +3.50% |
| 2003-12-31 | CN¥472.91 Million | +6.35% |
| 2002-12-31 | CN¥444.66 Million | +2.58% |
| 2001-12-31 | CN¥433.47 Million | +426.29% |
| 2000-12-31 | CN¥82.36 Million | +18.07% |
| 1999-12-31 | CN¥69.76 Million | +18.87% |
| 1998-12-31 | CN¥58.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhongzhu Medical Holdings Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24044.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥1.99 Billion | 113.93% |
| Other Comprehensive Income | CN¥122.56 Million | 7.01% |
| Other Components | CN¥2.90 Billion | 165.72% |
| Total Equity | CN¥1.75 Billion | 100.00% |
Zhongzhu Medical Holdings Co Ltd Competitors by Market Cap
The table below lists competitors of Zhongzhu Medical Holdings Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inter & Co Inc
SA:INBR32
|
$417.84 Million |
|
Cannae Holdings Inc
NYSE:CNNE
|
$417.92 Million |
|
Wenfeng Great World Chain Development Corp
SHG:601010
|
$417.93 Million |
|
Zydus Wellness Limited
NSE:ZYDUSWELL
|
$418.00 Million |
|
Hexatronic Group AB (publ)
PINK:HTROF
|
$417.76 Million |
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
$417.73 Million |
|
AlzChem Group AG
PINK:ALZCF
|
$417.65 Million |
|
Marimekko Oyj
PINK:MKKOF
|
$417.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhongzhu Medical Holdings Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,453,996,685 to 1,749,275,473, a change of -704,721,212 (-28.7%).
- Net loss of 620,220,648 reduced equity.
- Dividend payments of 324,381 reduced retained earnings.
- Share repurchases of 89,999,961 reduced equity.
- Other comprehensive income increased equity by 5,499,398.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-620.22 Million | -35.46% |
| Dividends Paid | CN¥324.38K | -0.02% |
| Share Repurchases | CN¥90.00 Million | -5.14% |
| Other Comprehensive Income | CN¥5.50 Million | +0.31% |
| Other Changes | CN¥324.38K | +0.02% |
| Total Change | CN¥- | -28.72% |
Book Value vs Market Value Analysis
This analysis compares Zhongzhu Medical Holdings Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.86x to 3.38x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | CN¥0.08 | CN¥3.06 | x |
| 1999-12-31 | CN¥0.10 | CN¥3.06 | x |
| 2000-12-31 | CN¥0.11 | CN¥3.06 | x |
| 2001-12-31 | CN¥0.60 | CN¥3.06 | x |
| 2002-12-31 | CN¥0.61 | CN¥3.06 | x |
| 2003-12-31 | CN¥0.63 | CN¥3.06 | x |
| 2004-12-31 | CN¥0.65 | CN¥3.06 | x |
| 2005-12-31 | CN¥0.61 | CN¥3.06 | x |
| 2006-12-31 | CN¥0.49 | CN¥3.06 | x |
| 2007-12-31 | CN¥0.49 | CN¥3.06 | x |
| 2008-12-31 | CN¥0.41 | CN¥3.06 | x |
| 2009-12-31 | CN¥0.63 | CN¥3.06 | x |
| 2010-12-31 | CN¥0.71 | CN¥3.06 | x |
| 2011-12-31 | CN¥0.89 | CN¥3.06 | x |
| 2012-12-31 | CN¥0.94 | CN¥3.06 | x |
| 2013-12-31 | CN¥1.00 | CN¥3.06 | x |
| 2014-12-31 | CN¥2.32 | CN¥3.06 | x |
| 2015-12-31 | CN¥1.72 | CN¥3.06 | x |
| 2016-12-31 | CN¥3.24 | CN¥3.06 | x |
| 2017-12-31 | CN¥3.01 | CN¥3.06 | x |
| 2018-12-31 | CN¥2.03 | CN¥3.06 | x |
| 2019-12-31 | CN¥1.85 | CN¥3.06 | x |
| 2020-12-31 | CN¥1.90 | CN¥3.06 | x |
| 2021-12-31 | CN¥1.81 | CN¥3.06 | x |
| 2022-12-31 | CN¥1.40 | CN¥3.06 | x |
| 2023-12-31 | CN¥1.21 | CN¥3.06 | x |
| 2024-12-31 | CN¥0.91 | CN¥3.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhongzhu Medical Holdings Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -118.96%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.21x
- Recent ROE (-35.46%) is below the historical average (-0.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 16.29% | 17.17% | 0.53x | 1.78x | CN¥3.69 Million |
| 1999 | 15.88% | 17.64% | 0.55x | 1.64x | CN¥4.10 Million |
| 2000 | 15.31% | 16.53% | 0.57x | 1.63x | CN¥4.37 Million |
| 2001 | 3.20% | 16.98% | 0.18x | 1.06x | CN¥-29.48 Million |
| 2002 | 2.52% | 12.33% | 0.19x | 1.08x | CN¥-33.28 Million |
| 2003 | 2.53% | 6.47% | 0.31x | 1.25x | CN¥-34.07 Million |
| 2004 | 1.85% | 1.94% | 0.59x | 1.63x | CN¥-38.62 Million |
| 2005 | -8.54% | -4.68% | 0.59x | 3.11x | CN¥-82.33 Million |
| 2006 | -24.30% | -5.85% | 1.13x | 3.67x | CN¥-122.27 Million |
| 2007 | 5.01% | 0.99% | 1.40x | 3.61x | CN¥-18.38 Million |
| 2008 | 9.90% | 1.65% | 1.49x | 4.01x | CN¥-422.47K |
| 2009 | 22.78% | 7.25% | 1.41x | 2.23x | CN¥82.22 Million |
| 2010 | 10.12% | 16.40% | 0.21x | 2.91x | CN¥877.83K |
| 2011 | 20.07% | 39.44% | 0.22x | 2.30x | CN¥91.86 Million |
| 2012 | 6.22% | 9.59% | 0.28x | 2.33x | CN¥-36.57 Million |
| 2013 | 6.06% | 7.90% | 0.30x | 2.56x | CN¥-40.61 Million |
| 2014 | 1.36% | 3.03% | 0.24x | 1.91x | CN¥-205.02 Million |
| 2015 | 3.01% | 7.96% | 0.21x | 1.76x | CN¥-170.34 Million |
| 2016 | 5.02% | 26.77% | 0.15x | 1.22x | CN¥-291.74 Million |
| 2017 | 2.83% | 17.26% | 0.13x | 1.21x | CN¥-429.55 Million |
| 2018 | -47.23% | -334.27% | 0.10x | 1.39x | CN¥-2.32 Billion |
| 2019 | -9.88% | -52.33% | 0.15x | 1.30x | CN¥-732.93 Million |
| 2020 | 0.08% | 0.44% | 0.16x | 1.19x | CN¥-376.39 Million |
| 2021 | -5.87% | -36.36% | 0.13x | 1.24x | CN¥-571.03 Million |
| 2022 | -28.57% | -157.97% | 0.14x | 1.33x | CN¥-1.08 Billion |
| 2023 | -14.02% | -53.86% | 0.21x | 1.23x | CN¥-589.34 Million |
| 2024 | -35.46% | -118.96% | 0.25x | 1.21x | CN¥-795.15 Million |
Industry Comparison
This section compares Zhongzhu Medical Holdings Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhongzhu Medical Holdings Co Ltd (600568) | CN¥1.71 Billion | 16.29% | 0.21x | $417.81 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |